In terms of tau modulation, the COG0102 (NCT02907567) trial reported that AD patients in the CT1812 treatment group showed an overall reduction in p-tau, with multiple phosphorylation sites affected and no difference in unphosphorylated tau concentration detected, which suggests that CT1812 may have an impact on tau-related pathology in AD (Table 1) [10]. Here, MAPT is linked to Alzheimer disease.